Cough syrup deaths in Gambia serious issue, says WHO chief scientist

Chief scientist at the WHO, Dr Soumya Swaminathan said the death of children in Gambia, potentially linked to four Indian-made cough syrups, was a serious issue

cough syrup, medicine, cold
File photo of cough syrup. Photo: Shutterstock
Press Trust of India Pune
1 min read Last Updated : Oct 21 2022 | 4:44 PM IST

Chief scientist at the World Health Organization (WHO) Dr Soumya Swaminathan on Thursday said the death of children in Gambia, potentially linked to four Indian-made cough syrups, was a serious issue.

Swaminathan was speaking to reporters on the sidelines of the annual general meeting of the Developing Countries Vaccine Manufacturers Network (DCVMN) here. A WHO report has linked the death of 66 children in Gambia to four Indian-made cough syrups. "Certainly, the government is in touch with WHO as WHO actually provided the report based on the investigation which was done to prove that it was because of the diethylene glycol contamination. It is a very serious issue and it has to be taken very seriously," said Swaminathan. In India there are central as well as state-level drug regulators and there is a need to harmonize their operations, she said. "There are no mechanisms where regulators of different states can actually work together, do the inspections on each other's products," she said. For India to remain a leader in generic medicines and vaccines space, it is important to prove that "we have a very strong regulatory system," she said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :WHOGambiaCough syrup

First Published: Oct 21 2022 | 6:36 AM IST

Next Story